Loading...
XSHG
603387
Market cap605mUSD
Dec 05, Last price  
8.44CNY
1D
0.12%
1Q
0.24%
IPO
-7.96%
Name

Getein Biotech Inc

Chart & Performance

D1W1MN
XSHG:603387 chart
P/E
19.14
P/S
3.67
EPS
0.44
Div Yield, %
2.25%
Shrs. gr., 5y
-0.15%
Rev. gr., 5y
3.77%
Revenues
1.16b
-14.93%
73,640,347154,195,412210,293,366276,420,264369,090,356488,582,766686,238,289968,204,2851,123,335,6181,401,701,3861,821,860,7031,369,162,2561,164,798,937
Net income
224m
-20.06%
21,960,30765,627,76175,135,877105,066,842138,356,904193,988,370249,612,047339,672,020304,733,135398,990,048498,909,980279,771,914223,636,488
CFO
423m
+23.52%
23,799,01359,715,98498,534,931121,729,000155,914,635191,912,890187,097,698225,732,761185,468,524432,364,576482,957,526342,439,889422,998,055
Dividend
Sep 19, 20240.09 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic products in China and internationally. The company provides diagnostic reagents and analyzers; calibrators; reagent raw materials, such as monoclonal and polyclonal antibodies, antigen, antiserum, and microsphere; and cardiac marker, inflammation, renal function, coagulation, thyroid function, fertility, diabetes care, and thrombus products. It also offers products in the area of cardiovascular, inflammatory, diabetes, fertility, renal, liver, and others. The company was founded in 2002 and is headquartered in Nanjing, China.
IPO date
Jul 17, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT